source
- Biogen to acquire RayThera for up to $1 billion as J&J shifts focus away from obesity to cancerBiogen announced an agreement to purchase RayThera for as much as $1 billion, marking the company's second takeover this year. The deal expands Biogen's portfolio into RayThera's pipeline, though s…
- Novocure's electric field therapy fails Phase 3 glioblastoma trial, not extending patient survivalNovocure announced on Thursday that its electric fields device, used together with standard chemoradiation, did not improve overall survival for patients with glioblastoma in a Phase 3 trial. The…